Noile-Immune BiotechTSE:4893 +4.07%53 Altman Z-Score is 49.30 as of Jul. 04, 2026, which is 16% below its 10-year median of 58.69. GuruFocus rates TSE:4893 with a GF Score™ of 53/100 and a GF Value™ of 円4.36 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 929 Biotechnology companies, Noile-Immune Biotech ranks better than 93.76% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 38.53 is strong.
Noile-Immune Biotech has a Altman Z-Score of 49.30, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Noile-Immune Biotech's Altman Z-Score or its related term are showing as below:
TSE:4893'
s Altman Z-Score Range Over the Past 10 Years
Min: 38.53 Med: 58.69 Max: 60.17
Current: 38.53
During the past 6 years, Noile-Immune Biotech's highest Altman Z-Score was 60.17. The lowest was 38.53. And the median was 58.69.
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
Noile-Immune Biotech Altman Z-Score Related Terms
Noile-Immune Biotech Altman Z-Score Historical Data
* Premium members only.
The historical data trend for Noile-Immune Biotech's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4893 vs VRTX, REGN, ALNY: Altman Z-Score Comparison
For the Biotechnology subindustry, Noile-Immune Biotech's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Noile-Immune Biotech Altman Z-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Noile-Immune Biotech's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Noile-Immune Biotech's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Noile-Immune Biotech's Altman Z-Score for today is calculated with this formula:
Z
=
1.2
*
X1
+
1.4
*
X2
+
3.3
*
X3
+
0.6
*
X4
+
1.0
*
X5
=
1.2
*
0.9769
+
1.4
*
-1.1186
+
3.3
*
-0.1464
+
0.6
*
83.6191
+
1.0
*
0.0011
=
49.30
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Noile-Immune Biotech (TSE:4893) has a Altman Z-Score of 49.30 as of Jul. 04, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Noile-Immune Biotech and its competitors. This is 16% below median its historical median of 58.69. Over the past decade, Noile-Immune Biotech's Altman Z-Score has ranged from 38.53 to 60.17. According to the industry distribution chart, Noile-Immune Biotech ranks #58 out of 929 companies in the Biotechnology industry, placing it in the top 6.2%.
Is Noile-Immune Biotech's Altman Z-Score too high?
Noile-Immune Biotech's current Altman Z-Score of 49.30 is 16% below median its 10-year median of 58.69. Over the past 10 years, this metric has ranged from a low of 38.53 to a high of 60.17. The Biotechnology industry median Altman Z-Score is 2.61. Noile-Immune Biotech's value of 49.30 is 1788.9% above this industry median. Based on the distribution chart, Noile-Immune Biotech ranks #58 out of 929 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Noile-Immune Biotech has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Noile-Immune Biotech's Altman Z-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Noile-Immune Biotech ranks #58 out of 929 companies for Altman Z-Score. This places Noile-Immune Biotech in the top 6% of its industry — outperforming the majority of peers. The industry median Altman Z-Score is 2.61. Noile-Immune Biotech's value of 49.30 is 1788.9% above this benchmark. Historically, Noile-Immune Biotech's own Altman Z-Score has ranged from 38.53 to 60.17 over the past decade. While the company's 10-year median is 58.69 vs. the industry median of 2.61, Noile-Immune Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Biotechnology company?
The median Altman Z-Score among Biotechnology companies is 2.61, based on 929 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Noile-Immune Biotech's current Altman Z-Score of 49.30 is 1788.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Noile-Immune Biotech and its competitors. For the Biotechnology industry, the median Altman Z-Score is 2.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Noile-Immune Biotech's current Altman Z-Score is 49.30, which is 16% below median its own 10-year median of 58.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Noile-Immune Biotech stock overvalued right now?
Based on GuruFocus' analysis, Noile-Immune Biotech (TSE:4893) is currently considered Significantly Overvalued. The stock's GF Value™ is 円4.36, compared to a current price of 円128.00 — trading 2835.8% above its estimated fair value. The current Altman Z-Score is 49.30, which is 16% below median its 10-year median of 58.69 and 1788.9% above the Biotechnology industry median of 2.61. Noile-Immune Biotech's overall GF Score™ is 53/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Noile-Immune Biotech (TSE:4893), the current Altman Z-Score is 49.30 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Noile-Immune Biotech (TSE:4893) Overvalued in 2026?
Based on GuruFocus' analysis, Noile-Immune Biotech stock appears to be overvalued.
The current stock price of 円128.00 is trading 2835.8% above its estimated GF Value™ of 円4.36.
GuruFocus considers Noile-Immune Biotech to be Significantly Overvalued.
Key valuation signals for TSE:4893:
Altman Z-Score: 49.30 (16% below median its 10-year median of 58.69)
GF Value™: 円4.36 vs. price of 円128.00 (2835.8% above fair value)
Industry Position: 1788.9% above the Biotechnology median (#58 of 929)
No single metric tells the full story. See the TSE:4893 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Noile-Immune Biotech Inc is engaged in the development of CAR-T cell therapy for solid cancers using its proprietary technology. The company's development pipeline and collaborative projects with other companies include different product candidates such as NIB102, NIB103, NIB104, ADAP01, AUTL01, etc. It operates in a single segment, the cancer immunotherapy drug discovery business.
53GF Score
Get the complete analysis for TSE:4893
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4893 has been successfully added to your 
